Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06644924 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma
A Phase 2 study of Asthma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
- 20
- Study locations
NCT06644924: Completed Phase 2 study of Asthma, sponsored by AstraZeneca.
NCT06644924 is a Phase 2 study of Asthma that has completed, run by AstraZeneca. The registered enrollment target is 118 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06644924, a Phase 2 study of Asthma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase II study, to investigate the therapeutic efficacy and safety of inhaled PT007 (referred to as AS MDI) compared with placebo MDI and open-label Ventolin Evohaler in male and female participants aged 18 to 65 years (inclusive) with asthma. This study consists of a screening/run-in period, a treatment period, and a follow-up phone call.
Primary Outcome
Change from baseline FEV1 measured at each time point for AS MDI and Ventolin Evohaler. Baseline FEV1 is the period specific mean of the available pre-dose values. Area Under the Curve (AUC) 0-6 hours is calculated using the trapezoidal rule and normalized by dividing by the time in hours from dosing to the last measurement included (i.e., \~ 6 hours).
Conditions Studied
Interventions
- COMBINATION_PRODUCT Intervention: AS MDI
- COMBINATION_PRODUCT Intervention: Ventolin Evohaler
- COMBINATION_PRODUCT Intervention: Placebo matching AS MDI
Study Locations (20)
California
- Research Site - Encinitas
- Research Site - Lancaster
- Research Site - Los Angeles
- Research Site - Newport Beach
- Research Site - San Diego
- Research Site - San Jose
- Research Site - Stockton
Florida
- Research Site - Clearwater
- Research Site - Miami
- Research Site - Tallahassee
- Research Site - Tampa
Missouri
- Research Site - Columbia
- Research Site - Saint Charles
- Research Site - St Louis
Oregon
- Research Site - Medford
- Research Site - Portland
Texas
- Research Site - Austin
- Research Site - El Paso
Maryland
- Research Site - White Marsh
North Carolina
- Research Site - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2025-02-10 |
| Est. Completion | 2025-06-04 |
| Phase | Phase 2 |
What the finished NCT06644924 record still lists
NCT06644924 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Intervention: AS MDI is the first listed.
NCT06644924 names 20 study sites across 7 states, led by California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT06644924 about?
NCT06644924 is a clinical study titled "A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma". Phase II study, to investigate the therapeutic efficacy and safety of inhaled PT007 (referred to as AS MDI) compared with placebo MDI and open-label Ventolin Evohaler in male and female participants aged 18 to 65 years (inclusive) with asthma. This study consists of a screening/run-in period, a tre...
What is the current status of trial NCT06644924?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2025-02-10. Estimated completion is 2025-06-04.
What conditions does trial NCT06644924 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06644924?
The interventions under investigation include: Intervention: AS MDI (COMBINATION_PRODUCT), Intervention: Ventolin Evohaler (COMBINATION_PRODUCT), Intervention: Placebo matching AS MDI (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06644924?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06644924 being conducted?
This trial has 20 study locations across California, Florida, Maryland, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06644924's enrollment target sits among peer trials
118 201st of 374 higher than 173 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI